Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Edgewise Therapeutics Q2 EPS $(0.34) Beats $(0.36) Estimate

Author: Benzinga Newsdesk | August 08, 2024 08:42am
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 5.56 percent. This is unchanged from the same period last year.

Posted In: EWTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist